MBX
MBX Biosciences, Inc.
Next earnings Aug 5, 2026 · consensus $-0.64 EPS
Last earnings +8.1% on 2026-05-07
$52.31
▲ +3.85%$52.31▲ +386.60%
over 1Y
L $9.75EODHDH $52.31
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.9%
1W+3.9%
1M+64.1%
3M+83.5%
YTD+71.2%
1Y+386.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Buy
Conservative balance sheet (liabilities/equity 0.04x).
Return on equity -23.6% · latest
MBX Biosciences, Inc. shows limited reported revenue, and -23.6% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$35.3M | -$68.2M | -$98.1M |
| Net income | -$32.6M | -$61.9M | -$87.0M |
| Diluted EPS | -$31.96 | -$5.82 | -$2.38 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.41B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-3.5%
FCF yield-3.3%
Quality & risk
ROIC (est.)-21.0%
Free cash flow-$81.9M
Total debt—
Net cash$75.3M
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+42.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-06-24open ↗8-KPeriod ending 2026-06-122026-06-12open ↗144Filing2026-06-10open ↗144Filing2026-06-09open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗8-KPeriod ending 2026-06-042026-06-05open ↗
Frequently asked
- Is MBX Biosciences, Inc. (MBX) a buy?
- MBX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.04x).
- What is MBX Biosciences, Inc.'s quality score?
- MBX scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001776111, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:13:41 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.